DHDavid Hallifax

David Hallifax

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Hallifax has a total of 138 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploring the Boundaries for In Vitro–In Vivo Extrapolation: Use of Isolated Rat Hepatocytes in Co-culture and Impact of Albumin Binding Properties in the Prediction of Clearance of Various Drug Types

    by Laura Francis, Kayode Ogungbenro, Tom De Bruyn, J. Brian Houston, David Hallifax

    Prediction of hepatic clearance of drugs (via uptake or metabolism) from in vitro systems continues to be problematic. This is particularly the case when plasma protein binding is high. The following work explores simultaneous assessment of both clearance processes, focusing on a commercial hepatocyte-fibroblast co-culture system (HµREL), over a 24 hour period, using a series of six probe drugs (ranging in metabolic and transporter clearance and low-to-high plasma protein binding). A rat hepatocyte co-culture prototype assay was established using drug depletion (measuring both medium and total concentrations) and cell uptake kinetic analysis, both in the presence (1 and 4%) and absence of plasma protein (BSA). Secretion of endogenous albumin was monitored as a marker of viability and this reached 0.004% in incubations (at a rate similar to in vivo synthesis). Binding to stromal cells was significant and required appropriate correction factors. Drug concentration-time courses were analysed both by conventional methods and a mechanistic cell model, prior to in vivo extrapolation. CL assayed by drug depletion in conventional suspended rat hepatocytes provided a benchmark to evaluate co-culture value. Addition of albumin appeared to improve predictions for some compounds (where fu<0.1); however, for high binding drugs, albumin significantly limited quantification and thus predictions. Overall, these results indicate the prospect of reliable measurement of hepatically cleared compounds, including (of novelty) those with low metabolic turnover but high active uptake, through the longevity of co-culture systems combined with judicious sampling. Significance Statement Co-culture systems, combining hepatocytes with stromal cells, offer a more advanced tool than standard hepatocytes, with the ability to be cultured for longer periods of time, yet their potential has not been comprehensively assessed. We evaluate the strengths and limitations of the HµREL system via the use of six drugs representing various metabolic and transporter-mediated clearance pathways with various degrees of albumin binding. Studies in the presence and absence of albumin allow IVIVE and a framework to maximise their utility.


  • Impact of Plasma Protein Binding in Drug Clearance Prediction: A Database Analysis of Published Studies and Implications for In Vitro-In Vivo Extrapolation

    by Laura Jane Francis, J.B. Houston, David Hallifax

    Plasma protein mediated uptake (PMU) and its effect on clearance (CL) prediction has been studied in various formats; however, a comprehensive analysis of the overall impact of PMU on CL parameters from hepatocyte assays (routinely used for IVIVE) has not previously been performed. The following work collated data, reflecting the effect of PMU for 26 compounds with a wide variety of physico-chemical, drug and in vivo CL properties. PMU enhanced the unbound intrinsic clearance in vitro (CLint,u in vitro), beyond that conventionally calculated using fu and was correlated with the unbound fraction of drug in vitro and in plasma (fup), and absolute unbound intrinsic clearance in vivo (CLint,u in vivo), in both rat and human hepatocytes. PMU appeared to be more important for highly bound (fup 50% of compounds predicted within a 2-fold error, for both rat and human datasets (n {greater than or equal to}100). Significance Statement Current strategies for prediction of hepatic CL from in vitro data are recognised to be inaccurate, but do not account for PMU. The impact of PMU on CLint,u in vitro is wide ranging and can be predicted based on fup and applied to CLint,u in vitro values obtained by standard procedures in the absence of plasma protein. Such PMU-enhanced predictions improved IVIVE, and future studies may easily incorporate this PMU relationship to provide more accurate IVIVE.


  • Open Access

    Use of Segregated Hepatocyte Scaling Factors and Cross-Species Relationships to Resolve Clearance Dependence in the Prediction of Human Hepatic Clearance

    by David Hallifax, James Brian Houston

    Human and rat hepatocytes have a strong tendency to underpredict hepatic intrinsic clearance (CLint) and the extent of under prediction increases with increasing observed CLint (Wood et al., 2017, Drug Metab and Dispos 45: 1178-1188). In the present study, application of the log average rat hepatocyte-rat in vivo empirical scaling factor (ESF) of 4.2 to human hepatocyte prediction (from the Wood et al database) successfully removed bias but did not improve precision. An analogous method, using individual drug rat ESFs only achieved marginal improvement in accuracy but not precision. A novel approach to resolve clearance-dependent prediction, involving rat ESFs calculated for particular (order of magnitude) ranges of observed CLint (log average range 0.12-2.1), improved human prediction precision but only modestly reduced bias. However, rat in vivo CLint was several-fold greater than human in vivo CLint and this was reflected in greater rat hepatocyte and microsome CLint, indicating that rat metabolic enzymes are more efficient than their human counterparts, by several-fold. By applying the segregated rat ESFs followed by the human-rat CLint ratio, which was consistent regardless of CLint (log average 3.5), both accuracy and precision were improved, providing a novel approach for prediction of human metabolic CLint involving rat hepatocytes. This capability of the cross-species approach indicates that underprediction from human in vitro systems is an intrinsic property of the in vitro system rather than a consequence of individual drug properties.


  • Importance of the Unstirred Water Layer and Hepatocyte Membrane Integrity In Vitro for Quantification of Intrinsic Metabolic Clearance

    by Francesca Leanne Wood, James Brian Houston, David Hallifax

    Prediction of clearance - a vital component of drug discovery - remains in need of improvement and, in particular, requires more incisive assessment of mechanistic methodology in vitro, according to a number of recent reports. Although isolated hepatocytes have become an irreplaceable standard system for measurement of intrinsic hepatic clearance mediated by active uptake transport and metabolism, lack of prediction reliability appears to reflect a lack of methodological validation, especially for highly cleared drugs, as we have previously shown. Here, novel approaches were employed to explore fundamental experimental processes and associated potential limitations of in vitro predictions of clearance. Rat hepatocytes deemed non-viable by trypan blue staining showed undiminished metabolic activity for probe P450 substrates midazolam and propranolol; supplementation with NADPH enhanced these activities. Extensive permeabilisation of the plasma membrane using saponin showed either full or minimal P450 activity depending on the presence or absence of 1 mM NADPH, respectively. Shaking of incubations facilitated P450 metabolic rates up to 5-fold greater than static incubation, depending on intrinsic clearance, indicating the critical influence of the unstirred water layer (UWL). Permeabilisation allowed static incubation metabolic rates to approach those of shaking for intact cells, indicating an artificially induced breakdown of the UWL. Permeabilisation combined with shaking allowed an increased metabolic rate for saquinavir, resolving the membrane permeability limitation for this drug. These findings advance the interpretation of the rate limiting processes involved in intrinsic clearance measurements, and could be critical for successful in vitro prediction.


  • Clearance Prediction Methodology Needs Fundamental Improvement: Trends Common to Rat and Human Hepatocytes/Microsomes and Implications for Experimental Methodology

    by Francesca Leanne Wood, James Brian Houston, David Hallifax

    Although prediction of clearance using hepatocytes and liver microsomes has long played a decisive role in drug discovery, it is widely acknowledged that reliably accurate prediction is not yet achievable despite the predominance of hepatically cleared drugs. Physiologically mechanistic methodology tends to underpredict clearance by several-fold and empirical correction of this bias is confounded by imprecision across drugs. Understanding of the causes of prediction uncertainty has been slow, possibly reflecting poor resolution of variables associated with donor source and experimental methods, particularly for the human situation. Hallifax et al. (Pharm. Res. 27: 2150-2161, 2010) reported that among published human hepatocyte predictions there was a tendency for underprediction to increase with increasing in vivo intrinsic clearance, suggesting an inherent limitation using this particular system. This implied an artefactual rate limitation in vitro, although preparative effects on cell stability and performance were not yet resolved from assay design limitations. Here, to resolve these issues further, we present an up-to-date and comprehensive examination of predictions from published rat as well as human studies (n= 128 and 101, hepatocytes and n= 71 and 83, microsomes, respectively) to assess system performance more independently. We report a clear trend of increasing underprediction with increasing in vivo intrinsic clearance which is similar both between species and between in vitro systems. Hence, prior concerns arising specifically from human in vitro systems may be unfounded and the focus of investigation in future should be to minimise the potential in vitro assay limitations common to whole cells and subcellular fractions.


  • Characterization of the comparative drug binding to intra- (liver fatty acid binding protein) and extra- (human serum albumin) cellular proteins

    by Andrew Rowland, David Hallifax, Matthew R. Nussio, Joseph G. Shapter, Peter I. Mackenzie, J. Brian Houston, Kathleen M. Knights, John O. Miners

    1. This study compared the extent, affinity, and kinetics of drug binding to human serum albumin (HSA) and liver fatty acid binding protein (LFABP) using ultrafiltration and surface plasmon resonance (SPR). 2. Binding of basic and neutral drugs to both HSA and LFABP was typically negligible. Binding of acidic drugs ranged from minor (fu > 0.8) to extensive (fu < 0.1). Of the compounds screened, the highest binding to both HSA and LFABP was observed for the acidic drugs torsemide and sulfinpyrazone, and for β-estradiol (a polar, neutral compound). 3. The extent of binding of acidic drugs to HSA was up to 40% greater than binding to LFABP. SPR experiments demonstrated comparable kinetics and affinity for the binding of representative acidic drugs (naproxen, sulfinpyrazone, and torsemide) to HSA and LFABP. 4. Simulations based on in vitro kinetic constants derived from SPR experiments and a rapid equilibrium model were undertaken to examine the impact of binding characteristics on compartmental drug distribution. Simulations provided mechanistic confirmation that equilibration of intracellular unbound drug with the extracellular unbound drug is attained rapidly in the absence of active transport mechanisms for drugs bound moderately or extensively to HSA and LFABP.


  • Top Cited Papers
    Open Access

    Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

    by Patricio Godoy, Nicola J. Hewitt, Ute Albrecht, Melvin E. Andersen, Nariman Ansari, Sudin Bhattacharya, Johannes Georg Bode, Jennifer Bolleyn, Christoph Borner, Jan Böttger, et al.

    This review encompasses the most important advances in liver functions and hepatotoxicity and analyzes which mechanisms can be studied in vitro. In a complex architecture of nested, zonated lobules, the liver consists of approximately 80 % hepatocytes and 20 % non-parenchymal cells, the latter being involved in a secondary phase that may dramatically aggravate the initial damage. Hepatotoxicity, as well as hepatic metabolism, is controlled by a set of nuclear receptors (including PXR, CAR, HNF-4α, FXR, LXR, SHP, VDR and PPAR) and signaling pathways. When isolating liver cells, some pathways are activated, e.g., the RAS/MEK/ERK pathway, whereas others are silenced (e.g. HNF-4α), resulting in up- and downregulation of hundreds of genes. An understanding of these changes is crucial for a correct interpretation of in vitro data. The possibilities and limitations of the most useful liver in vitro systems are summarized, including three-dimensional culture techniques, co-cultures with non-parenchymal cells, hepatospheres, precision cut liver slices and the isolated perfused liver. Also discussed is how closely hepatoma, stem cell and iPS cell-derived hepatocyte-like-cells resemble real hepatocytes. Finally, a summary is given of the state of the art of liver in vitro and mathematical modeling systems that are currently used in the pharmaceutical industry with an emphasis on drug metabolism, prediction of clearance, drug interaction, transporter studies and hepatotoxicity. One key message is that despite our enthusiasm for in vitro systems, we must never lose sight of the in vivo situation. Although hepatocytes have been isolated for decades, the hunt for relevant alternative systems has only just begun.